Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa
Background. Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson’s disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients. Methods. Data were collected from several p...
Main Authors: | Cindy Zadikoff, Werner Poewe, James T. Boyd, Lars Bergmann, Horia Ijacu, Pavnit Kukreja, Weining Z. Robieson, Janet Benesh, Angelo Antonini |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2020/9716317 |
Similar Items
-
Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
by: Werner Poewe, et al.
Published: (2020-06-01) -
A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies
by: James T. Boyd, et al.
Published: (2020-01-01) -
Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
by: Miho Murata, et al.
Published: (2018-02-01) -
LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
by: Luminita Celia POPA, et al.
Published: (2020-06-01) -
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)